← All indications
Stomach Neoplasms
Tumors or cancer of the STOMACH.
Drugs by status
Approved for this indication (2)
Phase 4 trials (61)
- gimeracil
- pravastatin
- tranexamic acid
- fentanyl
- somatostatin
- yiqi
- huaier
- droperidol
- esomeprazole
- procaine benzylpenicillin
- saccharomyces boulardii
- bismuth
- irinotecan
- tramadol
- amoxicillin
- nicotine
- bevacizumab
- ferric derisomaltose
- metronidazole
- magnesium sulfate
- trastuzumab
- morphine
- fatty acid
- ramucirumab
- ropivacaine
- adebrelimab
- clopidogrel
- reconvan
- ilaprazole
- rabeprazole
- +31 more
Phase 3 trials (113)
- sunflower oil
- gastrin 17 vaccine
- dihydroartemisinin
- balstilimab
- car t cells
- sodium thiosulfate
- atezolizumab
- trastuzumab emtansine
- tucatinib
- bl-m07d1
- escitalopram
- gemcitabine
- [f-18]fapi-74
- epirubicin
- olaparib
- tipiracil
- vitamin d3
- coriolus versicolor
- everolimus
- toripalimab
- Andecaliximab
- tea
- vitamin c
- pemetrexed
- vinorelbine
- ursodeoxycholic acid
- etoposide
- escherichia coli nissle 1917
- simvastatin
- tislelizumab
- +83 more
Phase 2 trials (351)
- tiragolumab
- sargramostim
- shr2554
- azd-4547
- budigalimab
- derazantinib
- autologous gp96 vaccination
- dasatinib
- q702
- romidepsin
- larotrectinib
- cbx-12
- psilocybin
- fludeoxyglucose f-18
- sitravatinib
- max-40279
- talazoparib
- matuzumab
- Filgrastim
- thor-707
- df6002
- u3-1402
- ls301
- bavituximab
- famotidine
- rosiglitazone
- bintrafusp alfa
- azd4360
- erlotinib
- celecoxib
- +321 more
Phase 1 trials (268)
- torl-2-307-adc
- eribulin
- alofanib
- sc-007
- asp2138
- ykl-40 peptide
- st-1898
- pimitespib
- emavusertib
- apg-5918
- Bismuth Subcitrate Potassium
- topotecan
- stk-012
- cgx1321
- bc001
- 89zr-lncab190
- nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
- iks014
- iam1363
- inbrx-106
- sgn-stnv
- inbrx-105
- hs-20093
- arx788
- andes-1537
- kk-lc-1 tcr-t cells
- sar443216
- kf-0210
- lithium
- petosemtamab
- +238 more
Other trials (78)
- urea
- pegulicianine
- l-glutamine
- glycopyrronium
- it-101
- graviola
- fialuridine
- ruxolitinib
- olive
- pyrazinamide
- polaprezinc
- sugammadex
- gabapentin
- her-2 icd peptide
- remifentanil
- hou gu mi xi
- zinc
- fibrinogen (human)
- arginine
- glucose
- formaldehyde
- carbon dioxide
- bvd-523
- human fibrin
- primaquine
- exendin (9-39)
- autologous dendritic cells
- triamcinolone
- 177lu-ctr-fapi
- methylene blue
- +48 more
Organizations
Organization Involved with Phase 4 Indications (38)
- Jilin University
- Osakidetza
- Tianjin Medical University
- Sun Yat-Sen University
- Hengrui Therapeutics, Inc.
- Temple University
- Nanjing Medical University
- Pontificia Universidad Catolica de Chile
- Abnoba
- Sir Run Run Shaw Hospital
- Takeda
- Il-Yang Pharm. Co., Ltd.
- Fudan University
- Capital Medical University
- University of Ulsan
- University of Chicago
- Latvian Biomedical Research and Study Centre
- Hallym University
- Karolinska Institute
- Mayo Clinic
- Shandong University
- Vanderbilt University
- Catalysis SL
- Pharmacosmos
- Technion University
- University of Nottingham
- Hebei University
- University of Latvia
- Zhengzhou University
- University of Helsinki
- +8 more
Organization Involved with Phase 3 Indications (183)
- Ishikawa Prefectural Central Hospital
- Ardeypharm GmbH
- Merck Serono
- University of Montpellier
- Changi General Hospital
- Yuebei People's Hospital
- Presidio Socio Sanitario Territoriale di Gorgonzola
- Sanofi
- Xinjiang Medical University
- Hutchison MediPharma
- Inje University
- LintonPharm Co.,Ltd.
- University of Cambridge
- Cha Medical University
- University of Tuebingen
- Eli Lilly
- Medical University of Lublin
- University of Hohenheim
- Shenzhen University
- University of Paris
- Japan Clinical Cancer Research Organization
- Trans Tasman Radiation Oncology Group
- Amgen
- Taizhou Hanzhong biomedical co. LTD
- European Organisation for Research and Treatment of Cancer
- GlaxoSmithKline
- A.O. TREVIGLIO-CARAVAGGIO
- Pusan National University
- BeOne Medicines
- Hanyang University
- +153 more
Organization Involved with Phase 2 Indications (255)
- China Medical University
- Boehringer Ingelheim
- Uppsala University
- Boston University
- Aventis
- Columbia University
- Clovis Oncology
- Ipsen
- SCRI Development Innovations
- The Second People's Hospital of Sichuan
- Shandong Tumor Hospital
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Simcere Pharmaceutical Co., Ltd
- Cancer Trials Ireland
- SWAN Isotopen AG, Bern
- Hefei University
- Neovii Biotech
- Xiamen University
- Leap Therapeutics, Inc.
- Case Western Reserve University
- University of Duisburg-Essen
- Translational Oncology Research International
- Xuzhou Medical University
- Eastern Cooperative Oncology Group
- University of Hamburg
- University of Southern California
- Celltrion
- Northwell Health
- University of Kansas
- Enzon
- +225 more
Organization Involved with Phase 1 Indications (64)
- Nanjing Sike Pharmaceutical Co., Ltd.
- Xiangxue Life Science Research Center
- AnewPharma
- Bukwang Pharmaceutical
- OncoTherapy Science, Inc.
- AbbVie
- Department of Veteran Affairs
- Cancer Research UK
- Bolt Biotherapeutics
- Ambrx
- CARsgen Therapeutics, Ltd.
- The University of Hong Kong
- Ludwig Institute for Cancer Research
- AltruBio
- William Marsh Rice University
- Genzada Pharmaceuticals
- Ghent University
- Green Cross Corporation
- Agensys, Inc.
- Celon Pharma SA
- Minneamrita Therapeutics LLC
- University of Nebraska
- SYZ Cell Therapy Co..
- North Shore Hospital, New Zealand
- Mirati Therapeutics Inc.
- Government of Poland
- Bellicum Pharmaceuticals
- Nordic Group BV
- Mie University
- Kom Op Tegen Kanker
- +34 more
Organization Involved with Other Experimental Indications (20)
- Ajou University
- Nanchang University
- Vitkovice Hospital
- Jiangxi University of Traditional Chinese Medicine
- Federal University of Santa Catarina
- Kaohsiung Medical University
- Medical University of Bialystok
- Chimei Medical Center
- University of Gothenburg
- Taiwan Cooperative Oncology Group
- University of Nantes
- Korea University
- McGill University
- Pavlov First Saint Petersburg State Medical University
- Sinobioway Cell Therapy Co., Ltd.
- Shantou University
- Changhua Christian Hospital
- Jiangxi Provincial Cancer Hospital
- North Wales Organisation for Randomised Trials in Health
- Shandong Golden Brick Biotechnology Co., Ltd.